Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522633 | 1.00 | TSHR (0.67) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL31222353 | 0.91 | TSHR (0.81) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL16220559 | 0.91 | TSHR (0.81) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL3660180 | 0.88 | NOTUM (0.69) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL29520673 | 0.88 | NOTUM (0.69) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL10422954 | 0.86 | TSHR (0.69) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL29520826 | 0.86 | NOTUM (0.67) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL29521106 | 0.86 | NOTUM (0.67) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL8343388 | 0.85 | NOTUM (0.83) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL5251752 | 0.85 | TSHR (0.67) | TSHRNOTUMSMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4251746-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA (FR) | 2023-10-04 | — | — | EP | claimed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
| EP-2694086-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | The Texas A&M University System (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138708-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-11 | — | — | WO | claimed |
| WO-2012135632-A2 | METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-04 | — | — | WO | claimed |
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1261340-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RES GROUP LLC (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| JP-2004500331-A | — | — | 2004-01-08 | — | — | JP | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| EP-1261340-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | Alpha Research Group, LLC (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | claimed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-6417177-B1 | Chloroquine derivatives for the treatment of Parkinson's disease | ALPHA RESEARCH GROUP, LLC | 2002-07-09 | — | — | US | disclosed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | TSHR 3114/4885NOTUM 3816/4885SMN1; SMN2 986/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | TSHR 4847/4885NOTUM 1359/4885SMN1; SMN2 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.